PEAK, NCT05208047: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
|
|
| Recruiting | 3 | 426 | Europe, Canada, US, RoW | CGT9486 plus sunitinib, CGT9486, Sunitinib, sunitinib - Part 1b, sunitinib - Part 2 | Cogent Biosciences, Inc. | Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | 07/25 | 09/26 | | |
NCT06208748: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST |
|
|
| Recruiting | 2 | 40 | US | Bezuclastinib in combination with sunitinib | Sarcoma Alliance for Research through Collaboration, Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group | Gastrointestinal Stromal Tumors, GIST | 06/26 | 06/27 | | |
